$NDRA Investors chase the GLP-1 drug boom, a critical bottleneck is emerging that could reshape the entire market—liver imaging simply doesn’t scale to meet the coming demand.
https://thestreetreports.com/endra-life-scien...ks-inside/
https://thestreetreports.com/endra-life-scien...ks-inside/